Matches in Wikidata for { <http://www.wikidata.org/entity/Q66060748> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q66060748 description "clinical trial" @default.
- Q66060748 description "ensayu clínicu" @default.
- Q66060748 description "klinisch onderzoek" @default.
- Q66060748 description "клінічне випробування" @default.
- Q66060748 name "Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer" @default.
- Q66060748 name "Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer" @default.
- Q66060748 type Item @default.
- Q66060748 label "Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer" @default.
- Q66060748 label "Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer" @default.
- Q66060748 prefLabel "Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer" @default.
- Q66060748 prefLabel "Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer" @default.
- Q66060748 P1132 Q66060748-D49092A6-C52B-43FE-A52B-C47501ADF91D @default.
- Q66060748 P1476 Q66060748-67B00059-8E29-4163-BC6E-57D38943D70E @default.
- Q66060748 P17 Q66060748-3B3C3AFE-945F-4C46-AE88-E57B610FBAFD @default.
- Q66060748 P1813 Q66060748-EF6349F0-7108-4AE8-9082-ADF3CCC35DED @default.
- Q66060748 P2899 Q66060748-0FB7A9BF-B7A5-4821-A01B-9BB7D86D61D7 @default.
- Q66060748 P3098 Q66060748-EB2B8190-5FB9-46A6-85E9-48A65D2CE60A @default.
- Q66060748 P31 Q66060748-189477C5-6470-464C-8FC3-0EC49AF0D297 @default.
- Q66060748 P4844 Q66060748-466FB5F1-14DE-40DE-AD72-21D6FF7E4C91 @default.
- Q66060748 P580 Q66060748-3DFEFC85-6811-4C2B-9E4C-A9BE545BE978 @default.
- Q66060748 P582 Q66060748-192385F1-8215-454D-AF25-093D76F4124F @default.
- Q66060748 P6099 Q66060748-75D24AC9-C199-4450-8DE3-D2A53CE9CBB6 @default.
- Q66060748 P6153 Q66060748-B5FF1DAC-7765-4E40-BB13-4991D6604AF0 @default.
- Q66060748 P8363 Q66060748-E403EF8E-1BEA-46CE-BFCD-DC9A692E1222 @default.
- Q66060748 P921 Q66060748-629B87F6-DA82-4CAF-A1FA-49211C31E4EB @default.
- Q66060748 P1132 "+29" @default.
- Q66060748 P1476 "A Phase II Clinical Trial of Pembrolizumab in Combination With the AE37 Peptide Vaccine in Patients With Metastatic Triple-Negative Breast Cancer" @default.
- Q66060748 P17 Q30 @default.
- Q66060748 P1813 "NSABP FB-14" @default.
- Q66060748 P2899 "+18" @default.
- Q66060748 P3098 "NCT04024800" @default.
- Q66060748 P31 Q30612 @default.
- Q66060748 P4844 Q13896859 @default.
- Q66060748 P580 "2019-05-03T00:00:00Z" @default.
- Q66060748 P582 "2023-06-30T00:00:00Z" @default.
- Q66060748 P6099 Q42824440 @default.
- Q66060748 P6153 Q115376 @default.
- Q66060748 P8363 Q78089383 @default.
- Q66060748 P921 Q7166532 @default.